Anthony G. Quinn Acquires 85,000 Shares of Generation Bio Co. (NASDAQ:GBIO) Stock

Generation Bio Co. (NASDAQ:GBIOGet Free Report) Director Anthony G. Quinn bought 85,000 shares of the company’s stock in a transaction that occurred on Monday, January 13th. The stock was acquired at an average price of $0.97 per share, with a total value of $82,450.00. Following the completion of the purchase, the director now directly owns 299,286 shares of the company’s stock, valued at approximately $290,307.42. The trade was a 39.67 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Generation Bio Stock Down 4.3 %

NASDAQ GBIO traded down $0.04 during trading hours on Tuesday, hitting $0.88. The company had a trading volume of 932,699 shares, compared to its average volume of 609,204. Generation Bio Co. has a fifty-two week low of $0.75 and a fifty-two week high of $4.65. The firm has a market cap of $58.78 million, a P/E ratio of -0.40 and a beta of 2.72. The business has a fifty day simple moving average of $1.35 and a 200-day simple moving average of $2.13.

Institutional Investors Weigh In On Generation Bio

Several large investors have recently modified their holdings of the stock. Rhumbline Advisers boosted its holdings in Generation Bio by 7.4% during the second quarter. Rhumbline Advisers now owns 78,903 shares of the company’s stock valued at $222,000 after acquiring an additional 5,430 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of Generation Bio by 2.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 423,299 shares of the company’s stock worth $1,046,000 after purchasing an additional 8,692 shares during the last quarter. Cubist Systematic Strategies LLC grew its holdings in Generation Bio by 91.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 19,046 shares of the company’s stock valued at $54,000 after buying an additional 9,075 shares during the last quarter. State Street Corp increased its position in Generation Bio by 1.2% in the 3rd quarter. State Street Corp now owns 992,188 shares of the company’s stock worth $2,451,000 after buying an additional 11,669 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Generation Bio by 8.7% during the second quarter. The Manufacturers Life Insurance Company now owns 164,573 shares of the company’s stock worth $464,000 after buying an additional 13,104 shares during the last quarter. 95.22% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Wedbush reaffirmed an “outperform” rating and set a $5.00 price target on shares of Generation Bio in a research report on Thursday, November 7th. Needham & Company LLC lowered their price target on Generation Bio from $10.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, January 8th.

View Our Latest Analysis on Generation Bio

About Generation Bio

(Get Free Report)

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.

See Also

Receive News & Ratings for Generation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Generation Bio and related companies with MarketBeat.com's FREE daily email newsletter.